Synta Pharmaceuticals, a US-based biopharmaceutical company, has named Dr Sumant Ramachandra as the new president of research and development (R&D).
Dr Ramachandra served as senior vice president, R&D, regulatory and medical affairs, and chief scientific officer of Hospira.
Prior to Hospira, he served as vice president and oncology portfolio therapeutic area lead at Merck. He also served as therapeutic area head for medical oncology at Pfizer, prior to Merck/Schering-Plough.
Synta president and CEO Safi Bahcall said, "Sumant brings a broad range of development and regulatory leadership experience, as well as a unique perspective having led both oncology development at large pharmaceutical companies, and the broader range of R&D functions at a large, global specialty pharma company."
Synta possesses chemical compound library, an integrated discovery engine, and a variety of clinical- and preclinical-stage drug candidates.
